betablocker titration — Competitive Intelligence Brief

betablocker titration (betablocker titration) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-adrenergic antagonist. Area: Cardiovascular.

marketed Beta-adrenergic antagonist Beta-1 and beta-2 adrenergic receptors Cardiovascular Small molecule

Target snapshot

betablocker titration (betablocker titration) — Policlinico Casilino ASL RMB. Beta-blockers inhibit the effects of catecholamines on beta-adrenergic receptors, reducing heart rate, contractility, and blood pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
betablocker titration TARGET	betablocker titration	Policlinico Casilino ASL RMB	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
Hydrocortisone/ Placebo and Propranolol	Hydrocortisone/ Placebo and Propranolol	University of Dundee	marketed	Glucocorticoid + Beta-blocker combination	Glucocorticoid receptor; Beta-1 and Beta-2 adrenergic receptors
Timolol 0.5% Ophthalmic Solution	Timolol 0.5% Ophthalmic Solution	University of California, Davis	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
RASi plus carvedilol	RASi plus carvedilol	Federal University of Minas Gerais	marketed	ACE inhibitor or ARB combined with non-selective beta-blocker	Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor
Brimonidine/Timolol mixed combination	Brimonidine/Timolol mixed combination	Seoul National University Hospital	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
Topical timolol maleate	Topical timolol maleate	Unity Health Toronto	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
Dorzolamide-timolol and latanoprost	Dorzolamide-timolol and latanoprost	Laboratorios Sophia S.A de C.V.	marketed	Fixed-dose combination of carbonic anhydrase inhibitor, beta-blocker, and prostaglandin F analog	Carbonic anhydrase II (dorzolamide), beta-1 and beta-2 adrenergic receptors (timolol), prostaglandin F receptor (latanoprost)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-adrenergic antagonist class)

1. Ain Shams University · 1 drug in this class
2. Policlinico Casilino ASL RMB · 1 drug in this class
3. Unity Health Toronto · 1 drug in this class
4. University of California, Davis · 1 drug in this class